RE: Webinar. Any Questions? Plenty I'd imagine.12 May 2025 13:57
Will be all dodged but...
1. You’ve said divesting Launch Diagnostics and the March-24 raise pushed the cash runway into Q1 2026 is this still the case? Once a Phase 2 AVA6000 and a Phase 1 AVA6103 are both running, what does the capital burn look like? How much capital gets us to the next value-inflection read-out?
2. Related to above. What is happening with Coris?
3. The Heights note still shows £25.5 m outstanding after the April conversion. Are you negotiating a buy-back or restructure, and under what conditions will you commit to cash-only repayments?
4. Does the AI collaboration give Tempus any right of first negotiation or data exclusivity that might scare off other potential partners?
5. Your March deck says you’re “seeking a partnership.” You have also said simon has been "very busy" in the past. What are the three biggest blockers BP still raises CMC, dataset depth, competitive landscape—and how are you tackling each?
6. The LG Chem/AffyXell deals used to headline things. Where do those programs sit now in terms of milestones, spend, and strategic priority?
7. On that note whatever happened to AVA3996 once seen as a super exciting product in the pipeline? It was tipped for the clinic in ’23. Is it on ice, partnered out, or quietly moving toward IND?